+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-09-26Number of Pages: 111

Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Anxiety Disorders and Depression Treatment Market
2.2 Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, By Geography, 2013 and 2020 (Value %)
 
Chapter 3 Global Anxiety Disorders and Depression Treatment Market Overview
3.1 Market Dynamics and Overview
3.2 Market Drivers
      3.2.1 Rising geriatric population expected to boost market growth
      3.2.2 Greater efficacy and reduced side effects of drugs in various classes likely to drive market growth
      3.2.3 Escalating prevalence of depression and anxiety disorders likely to contribute to market growth
3.3 Market Restraints
      3.3.1 Patent expirations of major drugs during the forecast period expected to impede market growth
      3.3.2 Dry pipeline of novel drugs is hindering market growth
      3.3.3 Drug resistant-mental disorders likely to challenge augmentation of the market
      3.3.4 Increasing number of generic drug variants might negatively affect market growth
3.4 Market Opportunities
      3.4.1 Improving distribution network in budding economies
      3.4.2 Development of herbal remedies
3.5 Porter’s Five Forces Analysis
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
3.7 Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography
3.8 Regulatory Framework
3.9 Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %)
 
Chapter 4 Global Anxiety Disorders and Depression Treatment Market, by Drug Class
4.1 Overview
      4.1.1 Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012 – 2020 (USD Million)
      4.1.2 Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
      4.1.3 Global Depression Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
4.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
      4.2.1 Global SSRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.2.2 Global SSRIs Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.3 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
      4.3.1 Global SNRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.3.2 Global SNRIs Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.4 Atypical Antipsychotics
      4.4.1 Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.4.2 Global Atypical Antipsychotics Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.5 Tricyclic Antidepressants (TCAs)
      4.5.1 Global TCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.5.2 Global TCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.6 Tetracyclic Antidepressants (TeCAs)
      4.6.1 Global TeCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.6.2 Global TeCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.7 Monoamine Oxidase inhibitors (MAOIs)
      4.7.1 Global MAOIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
               4.7.1.1 Global MAOIs Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.8 Benzodiazepines
      4.8.1 Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
      4.8.2 Global Benzodiazepines Market Revenue, by Depression, 2012 – 2020 (USD Million)
4.9 Beta-Blockers
      4.9.1 Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
4.10 Anticonvulsants
      4.10.1 Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
 
Chapter 5 Global Anxiety Disorders and Depression Treatment Market, Pipeline Analysis
5.1 Overview
5.2 Brintellix (Vortioxetine - Lu AA21004)
      5.2.1 Global Brintellix Market Revenue, 2014 – 2020 (USD Million)
5.3 Brexpiprazole (OPC-34712)
      5.3.1 Global Brexipiprazole Market Revenue, 2016 – 2020 (USD Million)
5.4 ALKS-5461
      5.4.1 Global ALKS-5461 Market Revenue, 2016 – 2020 (USD Million)
 
Chapter 6 Global Anxiety Disorders and Depression Treatment Market, by Geography
6.1 Overview
      6.1.1 Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million)
      6.1.2 Global Anxiety Disorders Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
      6.2.1 North America Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
6.3 Europe
      6.3.1 Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
      6.4.1 Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
      6.5.1 RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Recommendations
7.1 Emphasis on Developing Novel and Combination Products
7.2 Targeting Emerging Economies (China, Singapore, Brazil, Dubai, India, South Africa and Mexico) for Marketing Generic Pharmaceuticals
7.3 Strategic Partnership with Biopharmaceutical Organizations
 
Chapter 8 Company Profiles
8.1 AstraZeneca PLC
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Eli Lilly and Company
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 Forest Laboratories, Inc.
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 GlaxoSmithKline plc
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 H. Lundbeck A/S
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Johnson & Johnson
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Merck & Co., Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Pfizer, Inc.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Sanofi-Aventis
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
      8.9.5 Recent Developments

List of Figures
 
FIG. 1 Anxiety Disorders and Depression Treatment: Market Segmentation
FIG. 2 Global Depression Treatment Market, by Drug Class, 2013 (USD Million)
FIG. 3 Global Anxiety Disorders Treatment Market, by Drug Class, 2013 (USD Million)
FIG. 4 Global Anxiety Disorders and Depression Treatment Pipeline Drugs Market (USD Million)
FIG. 5 Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, by Geography, 2013 and 2020 (Value %)
FIG. 6 Anxiety Disorders and Depression Treatment Market, Drivers, and Restraints
FIG. 7 Porter’s Five Forces Analysis: Anxiety Disorders and Depression Treatment Market
FIG. 8 Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography
FIG. 9 Major Developments in Anxiety Disorders and Depression Treatment Market
FIG. 10 Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %)
FIG. 11 Global SSRIs Market Revenue, By Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 12 Global SSRIs Market Revenue, By Depression, 2012 – 2020 (USD Million)
FIG. 13 Global SNRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 14 Global SNRIs Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 15 Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 16 Global Atypical Antipsychotics Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 17 Global TCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 18 Global TCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 19 Global TeCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 20 Global TeCAs Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 21 Global MAOIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 22 Global MAOIs Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 23 Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 24 Global Benzodiazepines Market Revenue, by Depression, 2012 – 2020 (USD Million)
FIG. 25 Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 26 Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
FIG. 27 Global Brintellix Market Revenue, 2014 – 2020 (USD Million)
FIG. 28 Global Brexipiprazole Market Revenue, 2016 – 2020 (USD Million)
FIG. 29 Global ALKS-5461 Market Revenue, 2016 – 2020 (USD Million)
FIG. 30 North America Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
FIG. 31 Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
FIG. 32 Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
FIG. 33 RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
FIG. 34 AstraZeneca plc: Annual Revenue 2011 – 2013 (USD Million)
FIG. 35 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 36 Forest Laboratories, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 37 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 H. Lundbeck A/S: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 39 Johnson & Johnson: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 41 Pfizer, Inc.: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 42 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables
 
TABLE 1 Market Snapshot: Global Anxiety Disorders and Depression Treatment Market
TABLE 2 Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012 – 2020 (USD Million)
TABLE 3 Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
TABLE 4 Global Depression Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
TABLE 5 Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 6 Global Anxiety Disorders Treatment Market Revenue, by Condition, 2012 – 2020 (USD Million)


 
 
Back To Top